<DOC>
	<DOCNO>NCT00629876</DOCNO>
	<brief_summary>The purpose study determine safety tolerability peginesatide use treat anemia subject diagnose recurrent non-small cell lung cancer , breast cancer prostate cancer also receive taxane chemotherapy .</brief_summary>
	<brief_title>A Safety Tolerability Study Peginesatide Anemic Cancer Patients Receiving Cytotoxic Chemotherapy .</brief_title>
	<detailed_description>Currently approve erythropoiesis stimulate agent use successfully increase hemoglobin level , reduce fatigue anemia-related symptom , improve daily function , alleviate need transfusion red blood cell subject chronic kidney disease-related anemia cancer subject chemotherapy-induced anemia . Peginesatide ( hematide ) Injection parenteral formulation administration intravenous subcutaneous injection develop correction anemia patient chronic kidney disease , include patient dialysis patient dialysis , treatment patient anemia due concomitantly administer chemotherapy . This multicenter , open-label dose escalation study evaluate safety , tolerability , efficacy multiple dos peginesatide Injection subject refractory non-small cell lung cancer , breast cancer , prostate cancer . These subject must anemia diagnosed result taxane chemotherapy .</detailed_description>
	<criteria>Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Individuals one follow histologically confirm tumor : stage IIIB/IV nonsmallcell lung cancer metastatic breast cancer androgen insensitive prostate cancer schedule receive least 4 week chemotherapy , include taxane . Has progression relapse treatment least one regimen chemotherapy hormone therapy . Has hemoglobin value great equal 8 less 10.5 g/dL within 1 week prior administration study drug . Has Eastern Cooperative Oncology Group Performance Status 02 . Has one ferritin level great equal 100 ng/mL within 4 week prior study drug administration . Has one serum red cell folate level low limit normal within 4 week prior study drug administration . Has one vitamin B12 level lower limit normal within 4 week prior study drug administration . Has one absolute neutrophil count great equal 1.5 x 109/L within 1 week prior administration study drug . The subject serum creatinine less equal 1.5 mg/dL measure creatinine clearance great 60 mL/min . The subject one platelet count great equal 100 x 109/L within 1 week prior administration study drug . The subject Life expectancy great 4 month . The subject body mass index 18 30 kg/m2 , inclusive , prior study drug administration . The subject negative test result hepatitis B surface antigen , hepatitis C virus antibody Screening . Has history failure respond erythropoiesisstimulating agent treatment . Has treatment erythropoiesisstimulating agent past 4 week . Is known antibody erythropoiesisstimulating agent history Pure Red Cell Aplasia . Has receive Peginesatide previous clinical study therapeutic agent . Has history hypersensitivity allergy Peginesatide , erythropoiesisstimulating agent related compound . Has red blood cell transfusion within 4 week prior study drug administration . Has know hemoglobinopathy ( eg , homozygous sicklecell disease , thalassemia type , etc ) . Has know hemolytic condition . Has know blood loss cause anemia , iron deficiency anemia , anemia cause gastrointestinal bleeding . Has previous plan radiotherapy 30 % active bone marrow . Has donate 400 mL blood within 90 day precede begin study . Has know intolerance parenteral iron supplementation . Has receive IV iron within 1 week study drug administration . Has history bone marrow peripheral blood cell transplantation . Has central nervous system metastasis . Has history deep venous thrombosis , pulmonary embolism thrombotic event ( eg , stroke , myocardial infarction , etc . ) previous 6 month know history hypercoagulable disorder . Has uncontrolled , symptomatic inflammatory disease ( eg , rheumatoid arthritis , systemic lupus erythematosus , etc ) . Has poorly control hypertension per investigator 's judgment within 4 week prior study drug administration ( eg , systolic great equal 170 mm Hg diastolic great equal 100 mm Hg repeat reading ) . Has seizure 6 month prior study drug administration . Has advance chronic congestive heart failure New York Heart Association Class III IV . Has history presence abnormal electrocardiogram Screening , investigator 's opinion , clinically significant . Has know history human immunodeficiency virus . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define consumption 4 alcoholic drink per day ) within 1 year prior Baseline . Has aspartate aminotransferase alanine aminotransferase great 2.5 time upper limit normal ( aspartate aminotransferase alanine aminotransferase great 5 time upper limit normal liver metastasis present ) , active liver disease jaundice . Is currently take anticipate require anticoagulant aspirin ( eg , coumadin , ticlopidine , etc. ) . Has bilirubin great upper limit normal . Has pyrexia/fever great equal 39Â°C within 48 hour prior study drug administration . Has high likelihood early withdrawal interruption study ( eg , myocardial infarction within past 3 month , severe unstable coronary artery disease , stroke , respiratory , autoimmune , neuropsychiatric neurological abnormality , clinically significant medical disease condition within prior 6 month may , investigator 's opinion , interfere assessment followup subject ) . Has anticipate elective surgery study period . Has exposure investigational agent within 1 month prior administration study drug plan receipt study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>